Panzest 25000300 mg

Panzest 25000 is a pancreatic enzyme replacement product formulated with a proportionally higher lipase content relative to its protease and amylase content. It is used to improve digestion of dietary fats, proteins, and carbohydrates in patients with exocrine pancreatic insufficiency (EPI), thereby reducing steatorrhea and supporting nutrient absorption.

Established / Guideline-Supported Uses

• Exocrine pancreatic insufficiency due to chronic pancreatitis in adults
• Exocrine pancreatic insufficiency following pancreatectomy or other pancreatic surgery
• Exocrine pancreatic insufficiency associated with cystic fibrosis, in children and adults, using an appropriately dosed pancreatic enzyme product

Other Recognised Uses (Pancreatic Insufficiency of Other Origin)

• Pancreatic duct obstruction (for example, by a tumour)
• Malabsorption due to other conditions reducing delivery of pancreatic enzymes to the small intestine

Certain non-enteric-coated formulations of Panzest 25000 are used in combination with an acid-suppressing agent (such as a proton pump inhibitor), as directed by the physician, to protect enzyme activity from inactivation by gastric acid. Panzest 25000 is an adjunct to dietary management and does not replace medical nutrition therapy.

Each dosage unit of Pancreatin [High Lipase] contains a standardized mixture of porcine-derived pancreatic enzymes: lipase, amylase, and protease, formulated so that the lipase activity is proportionally higher relative to the amylase and protease activity compared with conventional pancreatin products. Potency is expressed in USP/BP lipase units (for example, 10,000 and 25,000 units of lipase per capsule), with correspondingly lower proportions of amylase and protease activity.

Panzest 25000 is an orally administered pancreatic enzyme replacement product derived from porcine pancreas. It is supplied as enteric-coated pellets within capsules (or as tablets, depending on brand) so that the enzymes are protected from degradation by gastric acid and are released mainly in the duodenum, where digestion of dietary fat, protein, and starch normally occurs.

As the name indicates, this "High Lipase" formulation of pancreatin is specifically formulated with an elevated lipase content relative to its other enzyme components, making it particularly suited to correcting fat malabsorption (steatorrhea) in patients with exocrine pancreatic insufficiency.

Pancreatic enzyme replacement therapy (digestive enzyme).

Pancreatin [High Lipase] supplies exogenous pancreatic enzymes that substitute for the patient's own deficient pancreatic secretions:

• Lipase hydrolyses dietary triglycerides into monoglycerides, glycerol, and free fatty acids, enabling their absorption; this activity is proportionally enriched in Pancreatin [High Lipase].
• Protease breaks down proteins into peptides and amino acids.
• Amylase hydrolyses starches into dextrins and simple sugars.

The enteric coating on most formulations protects the enzymes from inactivation by gastric acid and dissolves at duodenal pH, releasing the enzymes at the normal site of fat, protein, and starch digestion. The enzymes act locally within the gastrointestinal lumen and are not intended to be absorbed systemically.

Take Panzest 25000 with meals and snacks. Swallow capsules/tablets whole with plenty of liquid without crushing or chewing. If needed for patients unable to swallow whole, the capsule may be opened and its contents mixed with a small amount of soft, acidic food and taken immediately, followed by fluids; the mixture must not be stored for later use, and must not be added to non-acidic foods or held in the mouth.

Panzest 25000 acts locally within the gastrointestinal lumen with minimal systemic absorption, so clinically significant systemic drug interactions are not expected.

• Acid-reducing agents (proton pump inhibitors, H2-receptor antagonists, antacids): for certain non-enteric-coated pancreatic enzyme formulations, the physician may prescribe an acid-suppressing agent together with Panzest 25000 to protect enzyme activity from gastric acid; this is a deliberate therapeutic strategy rather than a harmful interaction, and does not apply to standard enteric-coated products.
• Iron-containing products: there are isolated reports that pancreatic enzyme products may reduce the absorption of oral iron; iron status may need monitoring if used together long-term.

Inform the physician or pharmacist of all other medicines being taken before starting Panzest 25000.

The most commonly reported side effects of Panzest 25000 are gastrointestinal and generally mild:

• Abdominal pain or discomfort, nausea, diarrhea or constipation, flatulence
• Headache

Serious but Less Common Effects

• Fibrosing colonopathy (colonic stricture) — reported mainly with prolonged use of very high doses, particularly in children with cystic fibrosis; presents with abdominal pain, distension, or worsening bowel symptoms and requires prompt medical evaluation.
• Hyperuricemia/hyperuricosuria — associated with high-dose use, more likely in patients with gout or renal impairment.
• Hypersensitivity reactions — ranging from skin rash and itching to, rarely, severe reactions such as anaphylaxis or bronchospasm, particularly relevant to patients with known porcine-protein allergy.
• Oral or perioral irritation if capsule contents are chewed or held in the mouth.

Panzest 25000 acts within the gastrointestinal tract with minimal systemic absorption, and available data have not shown it to cause fetal harm; however, well-controlled studies in pregnant women are limited. Panzest 25000 should be used during pregnancy only if clearly needed, and only if the potential benefit to the mother justifies any potential, unproven risk to the fetus; a physician should be consulted before use.

Because systemic absorption is minimal, Panzest 25000 is generally considered compatible with breastfeeding, but a physician should be consulted before use while breastfeeding, particularly for high-dose or prolonged therapy.

Fibrosing colonopathy: Prolonged use of very high doses of pancreatic enzyme products, including Panzest 25000, has been associated with fibrosing colonopathy, most notably in children with cystic fibrosis. Doses should always follow recommended weight-based limits and must not be increased beyond the maximum recommended dose without physician assessment. Any new or worsening abdominal symptoms during therapy, especially in children, should be evaluated promptly.

Hyperuricemia/hyperuricosuria: High doses have been associated with elevated blood or urinary uric acid. Use with caution and consider monitoring in patients with gout, hyperuricemia, or renal impairment.

Porcine-derived product: Panzest 25000 is derived from pig (porcine) pancreas. Patients who avoid porcine-derived products for religious, dietary, or personal reasons should be counselled about this before starting therapy, and alternative options may be discussed with the physician.

Administration technique: Do not crush or chew the capsules/tablets, and do not hold the contents in the mouth, as this can cause irritation of the oral mucosa and destroys the protective coating needed for the enzymes to work correctly.

Hypersensitivity: Discontinue and seek medical attention if signs of an allergic reaction (rash, swelling, difficulty breathing) occur; see Contraindications.

Specific data on acute overdose with Panzest 25000 are limited. Excessive or chronic supratherapeutic dosing has been associated with hyperuricemia/hyperuricosuria and, particularly with prolonged very high doses, fibrosing colonopathy (see Precautions and Warnings). Marked overdose may also cause gastrointestinal irritation, nausea, vomiting, diarrhea, or abdominal cramping, and oral/perianal irritation with high local concentrations.

If an overdose is suspected, seek immediate medical attention or contact a poison control centre/emergency services rather than attempting home treatment; management is supportive and should be directed by a physician.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment: No formal dose adjustment has been established; because high doses of Panzest 25000 can raise uric acid, use with caution and monitor renal function/uric acid in patients with pre-existing renal impairment.

Hepatic impairment: Specific dosing data are lacking; since systemic absorption is minimal, use is generally not expected to require adjustment, but the physician should be consulted.

Elderly: No specific dose adjustment has been established beyond standard weight-based dosing; use with attention to other comorbidities and concurrent medicines.

Pediatric patients: See Pediatric Uses.

Patients avoiding porcine products: As this is a porcine-derived product, counsel patients with religious or dietary restrictions before starting therapy (see Precautions and Warnings).

Panzest 25000 is typically used long-term, often for the lifetime of the underlying condition (for example, cystic fibrosis or chronic pancreatitis with confirmed exocrine pancreatic insufficiency), taken with every meal and snack for as long as pancreatic insufficiency persists. The physician periodically reassesses dose adequacy based on symptoms (steatorrhea, weight, growth in children) and nutritional status, and adjusts or discontinues therapy accordingly.

Pancreatic enzymes; Digestive enzyme replacement agents

Pancreatin [High Lipase] replaces deficient endogenous pancreatic enzymes. Its enriched lipase component hydrolyses dietary triglycerides into monoglycerides and free fatty acids for absorption; its protease component breaks proteins into peptides and amino acids; and its amylase component converts starches into dextrins and simple sugars. Enteric coating (where present) protects the enzymes from gastric acid and releases them at duodenal pH, the normal site of fat, protein, and starch digestion.

Panzest 25000 is used in children with confirmed exocrine pancreatic insufficiency, most commonly due to cystic fibrosis, using weight-based dosing individualized by an age/weight-based schedule (see Dosage and Administration): approximately 2,000–4,000 lipase units per 120 mL of formula or breast milk in infants, 1,000 lipase units/kg/meal (maximum 2,500 units/kg/meal) in children 1–4 years, and 500 lipase units/kg/meal (maximum 2,500 units/kg/meal) in children 4 years and older, not exceeding 10,000 lipase units/kg/day.

For some pancreatic enzyme products/formulations and indications (for example, non-enteric-coated products indicated specifically for chronic pancreatitis or pancreatectomy in adults), safety and efficacy in pediatric patients have not been established, and use in children should follow specialist/pediatric gastroenterology guidance. Children, especially those with cystic fibrosis on high doses, should be monitored for adequate growth/weight gain and for early signs of fibrosing colonopathy.